基于主成分分析结合频数统计构建心肌梗死中医临床疗效评价的终点指标

发布时间：2018-05-19 04:22

  本文选题：主成分分析 + 心肌梗死　； 参考：《辽宁中医杂志》2017年10期

【摘要】：目的:调查中医院心肌梗死患者住院期间及随访期间终点事件的发生情况,运用主成分分析结合频数统计构建心肌梗死中医临床疗效评价的终点指标。方法:采用病案调查及随访研究。纳入山东中医药大学附属医院、淄博市中医院、日照市中医院、青岛市中医院、济南市中医院、济宁市中医院6家中医院,2008年1月1日—2014年12月31日入院,出院诊断为心肌梗死患者。制作中医医院心肌梗死患者调查表。收集患者住院期间及随访期间一般资料及终点事件发生情况。将数据输入Excel2003及SPSS17.0软件包。运用主成分分析分别计算住院期间及随访期间各终点指标的权重,统计各指标发生频数,利用乘数合成归一法计算各指标的综合权重,结合临床意义,建立心肌梗死中医临床疗效评价的终点指标。结果:(1)住院期间:综合权重大小依次为梗死后心绞痛(0.2175)、血运重建(0.1624)、心源性死亡(0.1360)等。(2)随访期间:随访6个月内综合权重大小依次为再住院次数(0.3887)、梗死后心绞痛(0.149)、心源性死亡(0.1434)等。随访1年内综合权重大小依次为再住院次数(0.5229)、心源性死亡(0.1271)、梗死后心绞痛(0.1212)等。随访1年以上综合权重大小依次为再住院次数(0.4374)、再梗死(0.1702)、心源性死亡(0.17)等。结论:(1)住院期间:主要评价指标为心源性死亡、严重心律失常、急性心力衰竭,次要评价指标为心源性休克、梗死后心绞痛、血运重建。(2)随访期间:随访6个月内主要评价指标为心源性死亡、心力衰竭、严重心律失常,次要评价指标为再梗死、脑卒中、血运重建等。随访1年内主要评价指标为心源性死亡、再梗死、心力衰竭,次要评价指标为脑卒中、血运重建、梗死后心绞痛等。随访1年以上主要评价指标为再梗死、心源性死亡、严重心律失常,次要评价指标为脑卒中、梗死后心绞痛、血运重建等。
[Abstract]:Objective: to investigate the incidence of end-point events during hospitalization and follow-up in patients with myocardial infarction in traditional Chinese Medicine (TCM), and to construct the endpoints of TCM clinical efficacy evaluation of myocardial infarction by principal component analysis (PCA) combined with frequency statistics. Methods: medical record investigation and follow-up study were used. It is included in the affiliated hospitals of Shandong University of traditional Chinese Medicine, Zibo City traditional Chinese Medicine Hospital, Rizhao traditional Chinese Medicine Hospital, Qingdao traditional Chinese Medicine Hospital, Jinan City traditional Chinese Medicine Hospital, Jining traditional Chinese Medicine Hospital, 6 Chinese Medicine Hospitals from January 1, 2008 to December 31, 2014. The patients were diagnosed as myocardial infarction. To make the questionnaire of myocardial infarction patients in TCM hospital. Collect the general data and the occurrence of terminal events during hospitalization and follow-up. Input data into Excel2003 and SPSS17.0 software package. Principal component analysis (PCA) was used to calculate the weight of each end-point index during hospitalization and follow-up period, to calculate the occurrence frequency of each index, to calculate the comprehensive weight of each index by the method of multiplier synthesis normalization, and to combine with clinical significance. To establish endpoints for evaluating the clinical efficacy of myocardial infarction in traditional Chinese medicine (TCM). Results during the period of hospitalization, the overall weight was 0.2175U, 0.1624g, 0.1360).) during the follow-up period, the overall weight was 0.3887g, 0.149m, 0.149and 0.3887g respectively, and the weight was 0.2175U, 0.1624g, 0.1360) during the 6-month follow up, the total weight was 0.3887g, 0.149, 0.149a, respectively. Cardiac death 0.1434). The weight of the patients was 0.5229m, 0.1271g, 0.121212) during one year follow up and so on. The order of weight was: rehospitalization times (0.5229g), cardiogenic death (0.1271g). The comprehensive weight values of more than one year follow up were as follows: the number of rehospitalization was 0.4374, the number of re-infarction was 0.1702, the cardiac death was 0.17). Conclusion: during hospitalization, the main evaluation indexes were cardiogenic death, severe arrhythmia, acute heart failure, secondary evaluation index was cardiogenic shock, postinfarction angina pectoris, the main evaluation index was cardiogenic death, severe arrhythmia, acute heart failure, and postinfarction angina pectoris. During the follow-up period, the main indexes were cardiogenic death, heart failure, severe arrhythmia, and secondary indexes were re-infarction, stroke and revascularization. The main evaluation indexes were cardiac death, reinfarction, heart failure, and the secondary indexes were stroke, revascularization, postinfarction angina pectoris and so on. The main evaluation indexes were re-infarction, cardiogenic death, severe arrhythmia, and the secondary evaluation indexes were stroke, post-infarction angina pectoris, revascularization and so on.
【作者单位】： 山东中医药大学第一临床医学院;山东中医药大学附属医院心内科;山东中医药大学;
【基金】：国家自然科学基金(81373827) 山东省一流学科资助项目(中医学)
【分类号】：R259
，

本文编号：1908698